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mTor kinase is involved in cell growth, proliferation,
and differentiation. The roles of mTor activators,
Rheb1 and Rheb2, have not been established
in vivo. Here, we report that Rheb1, but not Rheb2, is
critical for embryonic survival andmTORC1 signaling.
Embryonic deletion of Rheb1 in neural progenitor
cells abolishesmTORC1 signaling in developing brain
and increases mTORC2 signaling. Remarkably,
embryonic and early postnatal brain development
appears grossly normal in these Rheb1f/f,Nes-cre
micewith the notable exception of deficits ofmyelina-
tion. Conditional expression of Rheb1 transgene in
neural progenitors increases mTORC1 activity and
promotes myelination in the brain. In addition the
Rheb1 transgene rescues mTORC1 signaling and
hypomyelination in the Rheb1f/f,Nes-cre mice. Our
study demonstrates that Rheb1 is essential for
mTORC1 signaling and myelination in the brain, and
suggests that mTORC1 signaling plays a role in selec-
tive cellular adaptations, rather than general cellular
viability.
INTRODUCTION
mTor kinase regulates multiple intracellular processes in re-
sponse to extracellular signals and nutrient availability, and is
an important therapeutic target in neurological disorders, brain
tumors, and immunology and diabetes research. mTor functions
as part of two distinct signaling complexes—mTORC1 and 2,
with mTORC1 consisting of mTor, mLST8, and Raptor, and
mTORC2 consisting of mTor, mLST8, Sin1, and Rictor (Jacinto
et al., 2006; Sarbassov et al., 2005a, 2005b). mTORC1 phos-
phorylates proteins involved in protein synthesis and cell growth,
including 4E-BP1 and p70S6 kinase 1 (S6K1), which phosphor-
ylates the ribosomal protein S6. mTORC2 phosphorylates AGC
(cAMP-dependent, cGMP-dependent, and protein kinase C)
kinase subfamilies such as the AKT/PKBs and all conventional
and atypical PKCs (Ikenoue et al., 2008), and is involved in the
regulation of actin cytoskeleton (Jacinto et al., 2004).DevelomTORC1 and 2 are activated by multiple growth factors,
including insulin and insulin-like growth factor1 (IGF1). For
example, insulin binding to the insulin growth factor receptor
initiates a signaling cascade that sequentially includes insulin
receptor substrate 1 and 2 (IRS1/2), phosphoinositide 3-OH
kinase (PI3K), PI3K-regulated serine/threonine kinase PKB
(also known as AKT), tuberous sclerosis complex 1/2 (TSC1/2),
and Rheb (Ras homolog enriched in brain) (Avruch et al., 2006;
Garami et al., 2003), whereas PKB/AKT phosphorylates
PRAS40—a Raptor-binding protein and releases its inhibitory
effect on mTORC1 (Sancak et al., 2007; Vander Haar et al.,
2007) . mTORC1 can also be activated by nutrients, e.g., amino
acids (Hara et al., 1998; Nobukuni et al., 2005) via Rag GTPase
(Sancak et al., 2008, 2010).
Rheb was identified based on its regulation as a cellular imme-
diate early gene in the brain (Yamagata et al., 1994). Based on
sequence homology, another Rheb-related family member
Rheb2 was identified (Tabancay et al., 2003); therefore, the orig-
inal Rheb is now known as Rheb1. Rheb1 mRNA is expressed in
all tissues, whereas Rheb2 is detectable in several peripheral
tissues but primarily expressed in brain, particularly in the
regions involved in higher cognitive function (Saito et al., 2005).
A role of Rheb in Tor signaling was revealed in functional screen
for genes that regulate the size of cells in Drosophila and was
placed upstream of Tor and downstream of TSC1/2 (Kwon
et al., 2003; Saucedo et al., 2003; Stocker et al., 2003; Zhang
et al., 2003). TSC1/2 exhibits GTPase-activating protein activity
toward Rheb, thus inhibiting Rheb activity (Inoki et al., 2003;
Zhang et al., 2003). For example, TSC1 and TSC2 inhibit
Rheb1 and mTORC1 signaling in the insulin pathway (Garami
et al., 2003). Rheb1 appears to activate mTORC1 via direct
binding to mTor (Long et al., 2005a), but the molecular basis
remains controversial. Both Rheb1 and Rheb2 transgenes can
activate mTor in heterologous cells.
Rheb has been linked to mTORC2 activity. Increasing Rheb1
activity by either overexpression of Rheb1 transgene or by
loss-of-function mutation of TSC1 or TSC2 increases mTORC1
activity but decreases mTORC2 activity (Garami et al., 2003;
Yang et al., 2006). This functional link between mTORC1 and
mTORC2 is mediated by a negative feedback mechanism
involving mTORC1/S6K1 activity inhibiting the transcription of
IRS1/2 and promoting degradation of IRS1/2 (Harrington et al.,
2004; Shah et al., 2004). Recently, S6K1 has been shown topmental Cell 20, 97–108, January 18, 2011 ª2011 Elsevier Inc. 97
Figure 1. Rheb1 Is Essential for Growth
Factor and Amino Acid-Stimulated
mTORC1 Signaling
(A) Western blots show the failure of serum-
starved primary Rheb1/ MEFs to activate
mTORC1 as indicated by pS6K and pS6 in
response to insulin stimulation (200 nM, 15 min).
(B) Western blots reveal normal response of
serum-starved Rheb1/ MEFs to insulin stimula-
tion (200 nM, 15 min) to activate mTORC2 (pAKT
S473) and ERK kinase. IRS1 and 2 are not upregu-
lated in the Rheb1/ MEFs. (C) Western blots
show the failure of Rheb1/ primaryMEFs to acti-
vate mTORC1 activity with AA stimulation. (D)
Immunostaining shows the restoration of the
mTORC1 activity in the Rheb1/ MEFs by myc-
Rheb1. DAPI staining (blue) reveals Rheb1/
MEFs not transfected with Rheb1 transgene.
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activity (Dibble et al., 2009; Gao et al., 2010; Julien et al., 2010;
Treins et al., 2010). However, studies of Rictor- and mLST8-
deficient mice indicate that mTORC2 activity is not required for
mTORC1 activation by serum/growth factor stimulation (Guertin
et al., 2006).
Despite progress in the understanding of mTor signaling, there
are no in vivo studies that indicate whether Rheb1 or Rheb2 is
necessary to activate mTor signaling. The importance of mTor
signaling in diverse aspects of cellular function, including protein
translation, suggests that it may be essential for organ develop-
ment and organismal survival. Indeed, mutations of genes that
are part of mTORC1 signaling complex, including mTor and
Raptor, have been reported to cause embryonic lethality (Gangl-
off et al., 2004; Guertin et al., 2006; Murakami et al., 2004). To
examine the contribution of Rheb in mTor signaling in vivo, and
to assess its role in tissue development, we established mouse
models that afford conditional genetic deletion of Rheb1 or
Rheb2, or conditional expression of Rheb1 transgene, and
examined brain development. Our studies demonstrate an
essential role of Rheb1, but not Rheb2, in mTORC1 signaling
in vivo, and confirm crosstalk between mTORC1 and mTORC2.
Additionally, we establish myelination as an important target of
Rheb1/mTORC1 signaling in brain.
RESULTS
Requirement of Rheb1, but Not Rheb2,
for Organism Viability
We generated mice with conditional genetic deletions of Rheb1
(see Figures S1A–S1C available online) and Rheb2 (Figures S1D
and S1E). Germline deletion of Rheb1 (Actin-cre) results in
embryonic death between E10.5 and E11.5. No viable homozy-
gous Rheb1 mutant embryos (Rheb1/) were identified after
E11.5. Heterozygous Rheb1 (Rheb1+/) embryos develop to
term, mature, and grow normally, and are fertile. Germline dele-
tion of Rheb2 does not affect embryonic viability, and mutant
mice mature to adulthood without obvious physical deficits.
Deletion of Rheb2 does not alter the survival of Rheb1/ or
Rheb1+/ mice because no offspring with the genotype of98 Developmental Cell 20, 97–108, January 18, 2011 ª2011 ElsevierRheb1/Rheb2/ were identified from intercrossing of Rheb1
and Rheb2 double-heterozygous mice, whereas offspring with
the genotype of Rheb1+/Rheb2/ were obtained at the ex-
pectedMendelian ratio. Thus, Rheb1, but not Rheb2, is essential
for organism viability.
Rheb1 Is Essential for Growth Factor
and Amino Acid-Stimulated mTORC1 Signaling
To examine Rheb1-dependent signaling, we cultured mouse
embryonic fibroblasts (MEFs) from individual E10.5 embryos
obtained by intercrossing of Rheb1+/ mice. Cell lysates were
assayed for Rheb1 protein and phospho-S6 (pS6), an indicator
of mTORC1 activation to phosphorylate S6 kinase (p70S6K1).
Rheb1 protein migrates at 17 kDa, as confirmed by its absence
in Rheb1/ MEFs. Although pS6 (S240/244) antibody reliably
detected phosphorylation in WT MEFs, it did not detect phos-
phorylation of S6 in primary Rheb1/ MEFs cultured with
0.5% serum (Figure 1A). Insulin induced a robust increase of
phosphorylation of p70S6 kinase and S6 in WT MEFs, but not
in Rheb1/ MEFs (Figure 1A). This was not due to reduced
expression of IRS1 or IRS2 (Figure 1B). Although the mTORC1
pathway was affected in the Rheb1/ MEFs, other insulin-
dependent signaling was preserved. Thus, insulin strongly
increased pERK (Figure 1B) in Rheb1/ MEFs. Moreover,
insulin increased pAKT(S473) (Figure 1B), which is selectively
phosphorylated by mTORC2 (Sarbassov et al., 2005b). Rheb2
mRNA was detected in the MEFs by RT-PCR (data not shown).
The absence of mTORC1 activity in Rheb1/ MEFs suggests
that Rheb2 is not able to compensate for the loss of Rheb1 in
the activation of mTORC1.
Amino acids potently activate mTor signaling (Hara et al.,
1998; Nobukuni et al., 2005), and the mTor pathway is consid-
ered critical for integration of growth factor signaling and nutrient
availability. Studies of signaling pathway(s) that mediate amino
acid-dependent activation of mTor are conflicting (Long et al.,
2005b; Smith et al., 2005). To examine the role of Rheb, MEFs
were grown in 0.5% FBS overnight and then subjected to
complete nutrient starvation (dPBS) for 2 hr, and subsequently
supplemented with amino acids for 1 hr. Amino acids stimulated
robust activation of mTORC1 in WT MEFs, as indicated byInc.
Figure 2. mTORC1 Is Selectively Impaired in the Rheb1f/f,Nes-cre
KO Brain
(A) Western blots show a drastic reduction in mTORC1 activity in the 4-week-
old Rheb1f/f,Nes-cre (hereafter, KO) brain, whereas the total level of S6 is not
altered relative to controls (hereafter, Ctr). (B) Western blots show significant
upregulation of mTORC2 activity in the 4-week-old Rheb1 KO brain and
concurrent upregulation of the activity of signaling components upstream of
Rheb1 (pAKT308 and pTSC2).
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MEFS, Rheb1/ MEFs failed to show any induction of pS6 or
pS6K1 under the same condition (Figure 1C). Serum-stimulated
S6phosphorylationwas rescued in Rheb/MEFsby expression
of myc-tagged Rheb1 (Figure 1D). These findings indicate that
Rheb1 is essential for growth factor and amino acid-stimulated
mTORC1 signaling in MEFs but is not required for mTORC2.
mTORC1 Activity Is Selectively Impaired
by Genetic Deletion of Rheb1
Toexamine the roles of Rheb1 inmTor signaling in vivo,wegener-
ated a mousemodel in which Rheb1 was conditionally excised in
neural progenitor cells using Nestin-cre (Nes-cre) driver line
(Rheb1f/f,Nestin-cre, referred to as Rheb1 KO in figure legends).
Nes-cre transgenic mice (Tronche et al., 1999) express Cre
activity as early as E10.5 that is typically restricted to neural
stem/progenitor cells that give rise to both neurons and glial cells
in the CNS. Nes-cre has been reported to excise floxed targets in
peripheral tissues, including excisions in germ cells. We con-
firmed deletion of Rheb1 by E15.5 (Figure S2A). Rheb1f/f,Nes-
cre mice were born at expected Mendelian ratios and appeared
normal at birth but showed postnatal growth retardation (Fig-
ure S2B). Rheb1f/f,Nes-cre mice survived up to 6 weeks after
birth. Consistent with data from MEFs, we found that in the
3- to 4-week-old mice, phosphorylation of S6 was robust in the
WT brains but was nearly absent in Rheb1f/f,Nes-cre brains,
despite normal levels of total S6 and S6K (Figure 2A). Nes-cre
provided highly efficient excision of Rheb1; however, a trace
amount of Rheb1 immunoreactivity remained in brain samples
and may underlie low-residual pS6 at S235/236 in some brain
regions. Alternatively, residual activity may be consistent with
the report that S6 kinase accounts for about 90%of phosphoryla-
tion of S6 in S6K1 and S6K2 double KOmice (Pende et al., 2004).
Although mTORC1 activity was reduced in the Rheb1f/f,Nes-
cre brain, mTORC2 activity was upregulated. mTORC2 activity
was assayed by phosphorylation of AKT at S473 and PKCa
at S657. Both phosphorylation indices were robust without
changes in the total levels of AKT and PKCa in Rheb1f/f,Nes-
cre brain (Figure 2B; Figure S2C), indicating preservation of
mTORC2 signaling. Indeed, comparisons with WT indicated
that mTORC2 signaling was substantially increased, consistent
with reported crosstalk between mTORC1 and mTORC2 in
heterologous cells (Julien et al., 2010; Rosner et al., 2009). An
examination of other signaling molecules that function in the
mTORC1 pathway revealed that phosphorylation of AKT (T308)
and TSC2 (T1462) were increased, whereas the levels of AKT
and TSC2 expression were not altered (Figure 2B). These data
are consistent with homeostatic adaptations of AKT and TSC
signaling because they normally function to increase Rheb
activity (Harrington et al., 2004; Shah et al., 2004).
Although Rheb1 is essential for mTORC1 signaling, we found
that Rheb2 is not essential for mTor signaling in vivo. Although
Rheb2 is expressed in multiple brain regions implicated in cogni-
tive function, we found that deletion of Rheb2 did not alter the
level of pS6, pAKT S473, or any other components in the mTor
pathway (Figures S2E–S2H). Deletion of Rheb2 in Rheb1+/
mice (Rheb2/Rheb1+/, 4 weeks old) appeared to trend
toward a modest reduction in pS6 and pAKT in the cortex and
hippocampus compared to Rheb2/, Rheb1+/, or WT mice,Develobut did not reach statistical significance (Figures S2F and
S2H). Accordingly, this analysis failed to detect a role for
Rheb2 in mTORC1 signaling in vivo.
Rheb1 Is Not Essential for Embryonic
Brain Development
The deletion of Rheb1 in neural progenitor cells by Nes-cre
afforded an opportunity to examine the role of Rheb1/mTORC1
in brain development. We confirmed the embryonic excision of
Rheb1 in the Rheb1f/f,Nes-cre mice by western blots showing
that Rheb1 protein level was reduced by >90% in the forebrain
of E15.5, E17.5, and P1 and P5 postnatal brains (Figure 3A;
Figure S2A). Consistent with the Rheb1 protein reduction, the
level of pS6 (S235/236 and S240/244) in the forebrains was
markedly reduced at P1 and P5, compared to age-matched
controls (Figure 3A). Nissl staining revealed that at P1 and P5,
the gross morphology of the brain of the Rheb1f/f,Nes-cre
mice was preserved. The brain weight at P1 was identical
between WT and Rheb1f/f,Nes-cre mice (Figure S3A). However,
by P5–P9, the weight of Rheb1f/f,Nes-cre brains was reduced,pmental Cell 20, 97–108, January 18, 2011 ª2011 Elsevier Inc. 99
Figure 3. Rheb1 Is Not Essential for the
Formation of the Brain During Embryonic
Development
(A) Western blots show no changes in neuronal
markers (NeuN, Tuj1, Tau1, andMAP2), and astro-
cyte marker (GFAP) in E17.5 to P5 Rheb1 KO
brains. A representative blot from three indepen-
dent experiments is shown. (B) Nissl staining
reveals the preservation of the gross morphology
of the brain structure in the P1 and P5 Rheb1 KO
mice, albeit at a reduced size. Bar, 500 mm. Note
the reduction in the thickness of the cortex. Scale
bar, 100 mm. (C) Immunostaining shows normal
genesis of OPCs in the corpus callosum of P2
KO brain. Insets show higher magnification of the
cells indicated by arrows. Scale bar, 20 mm. Data
represent mean ± SEM. Results are averages of
two independent experiments.
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development (Figure 3B; Figure S3A). By 2–3 weeks, the weight
of the Rheb1f/f,Nes-cre brain was 50% of that of WT controls
(Figure S3A). The cortical thickness of the Rheb1f/f,Nes-cre
brain was 65% of WT controls at 4 weeks old (Figure S3B).
There is no loss of neurons in the Rheb1f/f,Nes-cre brain
because Nissl and NeuN staining of P1, P5, and P28 did not
reveal a reduction in neuronal counts (Figure 3B; Figures S3C
and S3D). Biochemical analysis revealed normal expression of100 Developmental Cell 20, 97–108, January 18, 2011 ª2011 Elsevieg
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MAP2 (Figure 3A), and the astrocyte
marker GFAP in the early postnatal
Rheb1f/f,Nes-cre brains (Figure 3A).
GFAP staining of early postnatal (P0 and
P2) and young adult (3–4 weeks old)
Rheb1f/f,Nes-cre brains showed normal
appearance of astrocytes (Figure S3E).
The number of oligodendrocyte precur-
sor cells (OPCs) indicated by NG2 and
PDGFRa in the P2 brain was comparable
to that in the control (Figure 3C), suggest-
ing the commitment of neural stem cells
into oligodendrocyte lineage cells was
not impaired.
Loss of Rheb1 Affects Postnatal
Myelination in the Brain
Patients with TSC and mouse models of
TSC showwhitematter/myelin abnormal-
ities (Meikle et al., 2007; Ridler et al.,
2001); therefore, we examined the myeli-
nation in the Rheb1f/f,Nes-cre mice.
Rheb1f/f,Nes-cre mice exhibited promi-
nent hypomyelination. Western blots of
4-week-old brain revealed reductions in
myelin proteins, including myelin basic
protein (MBP), 20,30-cyclic nucleotide 30-
phosphodiesterase (CNP), phospholipo-
protein (PLP), myelin-associated glyco-
protein (MAG), myelin oligodendrocytelycoprotein (MOG), and myelin-associated oligodendrocyte
asic protein (MOBP) in Rheb1f/f,Nes-cre mice compared with
ontrols (WT, Rheb1f/f or Rheb1+/+, Nes-cre) (Figures 4A and
B). Similar reductions were evident in cortex, hippocampus,
nd cerebellum. mRNA levels for these myelin proteins were
lso reduced in the Rheb1f/f,Nes-cre brain (Figure 4C). A reduc-
on in themyelin proteins in the Rheb1f/f,Nes-cre was also noted
2-week-old brain (Figure S4A), an early stage of myelination in
e brain. Most Rheb1f/f,Nes-cre mice die when they are
Figure 4. Rheb1 Regulates Postnatal Myelination
in the Brain
(A) Western blots show the reduction in myelin proteins in
the 4-week-old Rheb1 KO brain. CTX, cortex; HIP, hippo-
campus; CB, cerebellum. (B) Histograms show quantifica-
tion of the reduction in myelin proteins in the cortex and
hippocampus of 4-week-old Rheb1 KO brain. Data repre-
sent mean ± SEM. Results are averages of three indepen-
dent experiments. (C) Quantitative RT-PCR shows the
reduction in mRNA of myelin genes in the cortex of
the 3-week-old Rheb1 KO brain. Data represent mean ±
SEM. Results are averages of three independent experi-
ments. (D) Immunostaining with MBP antibody shows
widespread hypomyelination in the cortex and hippo-
campus of the 3-week-old Rheb1 KO brain. Scale bar,
100 mm. (E) Black Gold staining shows hypomyelination
in the cortex and corpus callosum of 3-week-old KO brain.
Scale bar, 100 mm. (F) LFB staining shows dramatic hypo-
myelination in the corpus callosum (CC) and striatum of
3-week-old Rheb1 KO brain. Arrows indicate the LFB-
positive areas in control and comparable areas in Rheb1
KO brain. Scale bar, 1 mm. Insets show higher magnifica-
tion of the boxed regions. Bar, 200 mm. (G) Electron
microscopy shows the reduction of myelinated axons of
the corpus callosum in the 3-week-old Rheb1 KO. Unmy-
elinated axons are indicated by red asterisk. Scale bar,
500 nm.
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later stages. Immunostaining of brain from 3-week-old Rheb1f/
f,Nes-cre mice with anti-MBP antibody revealed widespread
loss of fineMBP reactive fibers in all cortical layers and in neuropil
regions of hippocampus (Figure 4D). BlackGold (Savaskan et al.,
2009) and Luxol Fast Blue (LFB) staining confirmed a reduction in
myelination in regionswith densewhitematter tracts aswell, e.g.,
the cingulum bundles and corpus callosum, striatum, and cere-
bellum (Figures 4E and 4F; Figures S4D and S4E). ElectronDevelopmental Cell 20, 9microscopy analysis of the corpus callosum re-
vealed a marked reduction in the number of
myelinated axons (Figure 4G). However, the
few remaining myelinated axons in the Rheb1f/
f,Nes-cre brain exhibited comparable thickness
of myelin sheath, as measured by g-ratio (data
not shown). Myelination in the optic nerves of
the Rheb1f/f,Nes-cre mice was similarly
reduced, as shown by western blots and elec-
tron microscopy (Figures S4B and S4F).
Myelin is generated by mature oligodendro-
cytes that express adenomatous polyposis
coli (APC) or known as CC1marker. The number
of CC1+Olig2+ cells was reduced by 60%–70%
in multiple regions, including corpus callosum,
cortex, and hippocampus of Rheb1f/f,Nes-cre
mice (Figures 5A and 5B; Figures S5A and
S5B), suggesting that lack of mature oligoden-
drocytes could account for the hypomyelination
in the Rheb1f/f,Nes-cre brain. The number of
OPCs, which are identified asNG2+/ PDGFRa+,
increased in the cortex and hippocampus
(Figures 5C and 5D; data not shown), but notin the corpus callosum (Figures 5C and 5D). NG2 protein expres-
sion increased in cortex, hippocampus, and cerebellum (Fig-
ure 5E). The number of Olig2 cells (representing all oligodendro-
cyte lineage cells) is reduced in the Rheb1f/f,Nes-cre brain,
particularly in the corpus callosum (50% reduction), less so in
the cortex and hippocampus (Figures 5A and 5B; Figures S5A
and S5B). Consistent with the reduction in the number of
Olig2+ cells, we found that Olig2 protein level is reduced by
50% in the cortex and hippocampus (data not shown). Although7–108, January 18, 2011 ª2011 Elsevier Inc. 101
Figure 5. Differentiation of OPCs into Postmitotic Oligodendrocytes Is Impaired in the Rheb1 KO
(A and B) Immunostaining shows the reduction in the number of postmitotic oligodendrocytes (CC1+Olig2+) in the corpus callosum of 2- to 3-week-old Rheb1 KO
brain (n = 3). Scale bar, 20 mm. Data represent mean ± SEM (**p < 0.01). (C and D) Immunostaining shows increased number of OPCs in the cortex but normal
number of OPCs in the corpus callosum of 3-week-old Rheb1 KO brain (n = 3). Arrows indicate the NG2/PDGFRa double-positive cells. Scale bar, 20 mm. Data
represent mean ± SEM (**p < 0.01). (E) Western blots show increasing amount of NG2 proteins in the cortex, hippocampus, and cerebellum of 3- to 4-week-old
Rheb1 KO mice.
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number appears not sufficient to make up for the loss of postmi-
totic oligodendrocytes that are Olig2 and CC1 double-positive.
These data indicate that hypomyelination in the Rheb1f/f,Nes-
cre brain is linked to reduced numbers of mature oligodendro-
cytes that produce myelin proteins but not due to a reduction
of OPCs. It is possible that the loss of Rheb1 affects the differen-
tiation of OPCs into postmitotic, myelinating oligodendrocytes.
Rheb1 Transgene Promotes Myelination
The observation of hypomyelination in the Rheb1f/f,Nes-cre
brain raises an intriguing question whether increasing Rheb1/
mTORC1 activity promotesmyelination, or causes hypomyelina-
tion, as predicted by the hypomyelination noted in TSC1 or TSC2
KOmouse (Meikle et al., 2007; Way et al., 2009) and attributed to
increased mTORC1 activity (Meikle et al., 2007). To answer this
question we generated a Cre recombinase-dependent condi-
tional Rheb1 transgenic mouse, in which a myc-tagged mutant
form of Rheb1 (S16H) was knocked into Rosa26 locus (Figures102 Developmental Cell 20, 97–108, January 18, 2011 ª2011 ElsevieS6A and S6B). Rheb1 S16H is relatively resistant to TSC
GTPase-activating activity (Yan et al., 2006). In this Rosa26-
Rheb1 S16H knockin mouse (Rheb1k/+, Nes-cre), the myc-
tagged Rheb1 cDNA is preceded by a floxed transcriptional
‘‘stop’’ signal, and transcription of Rheb1 is dependent on
removal of the ‘‘stop’’ by cre- recombinase. The expression of
Rheb1 S16H transgene was validated by anti-myc and anti-
Rheb1 antibodies (Figure S6C). The expression of Rheb1 S16H
transgene increased mTORC1 activity and reduced mTORC2
activity (Figure S6D). Mice heterozygous or homozygous for
Rheb1 S16H transgene (with the genotype of either k/+, Nes-cre
or k/k, Nes-cre, respectively) are born with predicted Mendelian
frequency and were viable through adulthood (>2 months).
The Rosa26-Rheb1k/k, Nes-cre mice exhibited enlarged brain
size with increased brain weight, increased thickness of cortex,
and an increase in size of the soma of cortical neurons (layers
one to six) (Figure S6E–S6H). Expression of myelin proteins
was prominently increased during early postnatal stage
(P8–P14) in cortex andhippocampus (Figures 6A–6C; FigureS6I),r Inc.
Figure 6. Rheb1 Transgene Promotes Myelination
(A) Western blots show increasing amount of myelin proteins in the brain of 2-week-old Rheb1 transgenic (Tg, k/k,Nes-cre) mice relative to controls (k/k or k/+)
and comparable amount of myelin proteins in the 3-month-old Rheb1 Tgmice. (B and C) Histograms show quantifications of myelin protein andmTORC1 activity
in the cortex of Rheb1 Tg mice. Data represent mean ± SEM. Results are averages of three independent experiments. (D) Immunostaining with MBP antibody
shows enhanced myelination in the corpus callosum (CC), cingulum bundles (Cing), and cortex (CTX) at P7 and P14 and normal myelination at P28. Arrows indi-
cate the MBP positive labeling. Scale bar, 20 mm. (E and F) Immunostaining with CC1 and Olig2 antibody shows increased postmitotic oligodendrocytes in the 1-
week-old Rheb1 Tg mice compared with controls (k/k; k/+). Arrows indicate the NG2/PDGFRa double-positive cells. Scale bar, 50 mm. Data represent mean ±
SEM. Results are averages of three independent experiments. (G) Histogram shows comparable number of postmitotic oligodendrocytes in the 2-week-old
Rheb1 Tg mice revealed by immunostaining. Data represent mean ± SEM. Results are averages of three independent experiments.
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the young (4–6 weeks old) and old (3 months old) adult mice
(Figures 6A–D; Figures S5J and S6K). This enhancedmyelination
is associated with an increase in the number of Olig2+/CC1+
mature oligodendrocytes at P7 (Figures 6E and 6F). By P14 there
was no difference between Rheb1k/k, Nes-cre versus controlDevelop(Rheb1k/k) (Figure 6G), suggesting that enhanced mTORC1
signaling results in precocious myelination. Importantly,
increasing Rheb1/mTORC1 did not cause hypomyelination in
the brain. This point is further supported by electron microscopy
revealing comparable myelination in the corpus callosum of 2-
month-old mice (Figure S6L).mental Cell 20, 97–108, January 18, 2011 ª2011 Elsevier Inc. 103
Figure 7. Conditional Expression of Rheb1
Transgene Restores mTORC1 activity and
Myelin Formation in the Rheb1 KO Brain
(A) Western blots show the expression of one copy
of Rheb1 S16H transgene (indicated by an
asterisk) ismore than sufficient to restore pS6 level
in the cortex of 4-week-old Rheb1 KO brain. The
pAKT level in the rescued Rheb1 KO (Rheb1f/
f,k/+,Nes-cre) brain is lower than that in the
control. (B) Western blots show restoration of
myelin proteins in the cortex of 4-week-old
rescued Rheb1 KO (f/f,k/+,Nes-cre) brain. (C)
Quantitative RT-PCR shows normal levels of
mRNA of myelin genes in the cortex of 3- to 4-
week-old, rescued Rheb1 KO (f/f,k/+,Nes-cre)
mice. Data represent mean ± SEM. Results are
averages of four independent experiments. (D
and E) MBP and Black Gold staining show
restored myelination in the hippocampus (D),
cortex, corpus callosum, and striatum (E) of
the 6- to 10-week-old, rescued Rheb1 KO
(f/f,k/+,Nes-cre). Scale bars, 100 mm in (D) and
1 mm in (E). (F) Histogram shows that the weight
of brain and body in the 3- to 5-month-old rescued
Rheb1 KO (f/f,k/+,Nes-cre) is comparable to that
of the controls. Data represent mean ± SEM. (G)
Immunostaining shows normal number of postmi-
totic oligodendrocytes (CC1+Olig2+) in the corpus
callosum of 6- to 10-week-old rescued Rheb1 KO
(f/f,k/+,Nes-cre) brain. Scale bar, 20 mm. Data
represent mean ± SEM. Results are averages of
two independent experiments.
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and Hypomyelination in Rheb1f/f,Nes-cre Brain
We crossed Rheb1 S16H transgene onto Rheb1f/f,Nes-cre
background and obtained mice with the genotype of
Rheb1f/f,k/+,Nes-cre (‘‘rescued’’ Rheb1f/f,Nes-cre) mice. In
these mice, Rheb1 transgene expression was detected, but
not native Rheb1 protein using Rheb1 specific antibody (Fig-
ure 7A). The expression of a single copy of Rheb1 S16H trans-
gene more than compensated the loss of native Rheb1, as indi-
cated by higher pS6 and lower pAKT level than in the control
(Rheb1f/f) (Figure 7A). Hypomyelination in the Rheb1f/f,Nes-cre
mice was rescued, as indicated by normal levels of myelin
proteins and mRNA in the brain (Figures 7B and 7C), and MBP
and Black Gold staining (Figures 7D and 7E). The number of
CC1+ cells in the corpus callosumwas also restored (Figure 7G).
Consistent with the restoration of mTORC1 function in the
Rheb1f/f,Nes-cre brain, the brain size and weight of the
‘‘rescued’’ Rheb1f/f,Nes-cre mice were comparable to that in
the control (f/+ or f/f,k/+) (Figures 7E and 7F). These findings
verify that Rheb1 is the causal agent in regulating mTORC1
activity and myelin formation in brain.104 Developmental Cell 20, 97–108, January 18, 2011 ª2011 Elsevier Inc.DISCUSSION
Rheb and mTor Signaling
The present study uses genetic
approaches to demonstrate that Rheb1
is necessary and sufficient for mTORC1
activation in vivo. Rheb1/ MEFs do
not respond to growth factor or amino acid stimulation to acti-
vate mTORC1, and mTORC1 activity was nearly absent in the
brain of Rheb1f/f,Nes-cre mice. mTORC1 activity was restored
to the normal level by the expression of a single copy of Rheb1
(S16H) transgene (Figure 7). Demonstration of the role of
Rheb1 in the activation of mTORC1 in vivo verifies earlier studies
using alternative approaches in heterologous cells (Garami et al.,
2003; Yang et al., 2006); e.g., the knock down of Rheb1 by siRNA
reduces insulin-stimulated activation of mTor/S6K/4E-BP1
signaling (Garami et al., 2003). The observation that Rheb1 is
essential for amino acid-dependent activation of mTORC1 is
consistent with a recent report that amino acids promote the
localization of mTor to a cellular compartment that contains
Rheb1 (Sancak et al., 2008, 2010). Together with the observation
that amino acid stimulation increases the amount of GTP-bound
Rheb in TSC2 mutant cells (Gulati and Thomas, 2007; Roccio
et al., 2006), our data support the notion that amino acid sensing
for mTORC1 occurs at a level upstream of TSC2. However,
mTORC1 is also reported to be activated by amino acids in
cells deficient for TSC1–TSC2 (Smith et al., 2005), suggesting
that the nutrient input to mTORC1 may also occur independent
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mechanisms are dependent on Rheb1.
Rheb1 is not required to activate mTORC2, consistent with the
notion that mTORC1 and 2 are regulated by distinct mecha-
nisms, as indicated by studies of Rictor or mLST8 mutant
MEFs. In these MEFs, mTORC2 activity is apparently absent;
however, mTORC1 activity can still be evoked by serum or
insulin stimulation (Guertin et al., 2006). We note that Rheb1f/
f,Nes-cre KO reduces the output of mTORC1 but increases
mTORC2 (pAKT S473) and IRS1 or 2 (Figure 2B; Figure S2D).
The upregulation of IRS1/2 may not fully account for the
increased mTORC2 in the Rheb1f/f,Nes-cre brain because
S6K1 has been shown to phosphorylate Rictor at T1135 and
results in a downregulation of mTORC2 activity (Dibble et al.,
2009; Gao et al., 2010; Julien et al., 2010; Treins et al., 2010).
Therefore, we envision that loss of S6K1 activity in Rheb1f/
f,Nes-cre KO would release the negative effect of phosphoryla-
tion of phosphor-Rictor (T1135) on mTORC2 activity. Reciprocal
adaptations occur in TSC1/2 KO (Harrington et al., 2004; Shah
et al., 2004). Together, these observations suggest that the
mTor-signaling network is subject to homeostatic adaptations
that may be important in understanding the pathogenesis of
diseases that impact mTor signaling in vivo.
The basis of postnatal growth defect of Rheb1f/f,Nes-cre mice
is likely due to mTORC1 signaling in neural tissues because we
found that mTORC1 signaling in hypothalamus was reduced
(Figure 2A), which may subsequently cause a defect in the
growth hormone production/secretion from anterior pituitary. It
is also possible that cre-activity is expressed in the pituitary
stem cells (Gleiberman et al., 2008), and deletion of Rheb1 in
these stem cells could affect the production/secretion of growth
hormones. Nes-cre has been reported to result in occasional
excision of floxed genes in peripheral tissues (Betz et al.,
1996). But in view of the essential role for Rheb1 in embryonic
development, this is unlikely to underlie the highly penetrant
growth defect in Rheb1f/f,Nes-cre mice. Additional studies that
conditionally delete Rheb1 in selective populations of neurons
will be informative.
Our studies do not reveal the function of Rheb2. Although
Rheb2 can activatemTor when overexpressed in vitro (Tabancay
et al., 2003), Rheb2 is not required for organismal viability, and is
not essential for mTORC1 or mTORC2 signaling, or myelination
(Figures S2E–S2G and S4C) in brain. Accordingly, alternative
functions for Rheb2 should be considered.
Rheb1 and Embryonic Brain Development
Rheb1 is required for the mid-stage embryonic viability. This is
consistent with the essential role of mTORC1 components
mTor and Raptor in the early embryonic development (Gangloff
et al., 2004; Guertin et al., 2006; Murakami et al., 2004) and is
not surprising in view of the many critical cellular functions
such as cell growth, proliferation, and differentiation ascribed
to mTORC1 signaling. What is notable is that a complex organ
such as brain can develop in the near absence of Rheb1/
mTORC1 signaling. Nes-cre activity is expressed as early as
E10.5 and results in effective excision in all types of neural cells
that populate the brain (Tronche et al., 1999). We have confirmed
that Rheb1 is reduced by >90% by western blotting with parallel
reduction of mTORC1 signaling by E17.5 (Figure 3). At this devel-Developopmental time, neural cells (neurons and glia) populating the
brain are still being generated. This suggests that Rheb1/
mTORC1 may not be essential for neural stem cells to differen-
tiate into neurons or for neurons to migrate and populate brain
structures during embryonic development and to function suffi-
ciently to support feeding and locomotion and survival of
5–6 weeks after birth. Because earlier studies of the ‘‘flat-top’’
mouse mutant created by ethyl-nitroso-urea (ENU) mutagenesis
show that a reduction of mTor activity underlies severe forebrain
defect and lack of telencephalon (Hentges et al., 1999, 2001), the
contrast with the present observations may be related to the
conditional deletion of Rheb or a role for mTORC2 in forebrain
development.
Rheb1 and Postnatal Myelination in the Brain
Rheb1f/f,Nes-cre mice display a prominent defect in myelination
during development. Previous studies have implicated mTor
signaling in the regulation of oligodendrocyte differentiation
and myelination. For example, inhibition of mTor signaling by
rapamycin or siRNA for Raptor (mTORC1) or Rictor (mTORC2)
inhibits the differentiation of cultured OPCs into postmitotic
oligodendrocytes expressing myelin genes such as MBP and
PLP (Tyler et al., 2009). Additionally, the differentiation of OPCs
is arrested at the late progenitor stage (O4+) by rapamycin treat-
ment, and the general cellular viability is not affected during the
course of rapamycin treatment, and chronic administration of
rapamycin in vivo counteracts the effect of transgenic expres-
sion of active AKT on promoting myelination in adult mice
(Narayanan et al., 2009). In the present study, effect of Rheb1
deletion on myelination is confirmed to be due to loss of
Rheb1 protein by genetic rescue and is likely dependent on
mTORC1 because this is the only validated function of Rheb1.
The reduction in the number of mature oligodendrocytes
together with the increase in the number of OPCs suggests
that Rheb1 is important in OPC differentiation. The Rosa-
Rheb1 S16H transgenic mouse further supports this notion
because at P7 the total number of oligodendrocyte lineage cells
(Olig2+) is not altered, but the number of postmitotic oligoden-
drocytes (CC1+) is significantly increased (Figures 6E and 6F).
The reduction in the number of CC1+ cells does not seem to
be due to increased cell death; we did not detect any increase
in cell death in 2- and 4-week-old Rheb1f/f,Nes-cre brain by TU-
NEL staining (data not shown). It is also possible that in the
Rheb1f/f,Nes-cre brain, OPCs can still differentiate into postmi-
totic, nonmyelinating oligodendrocytes that express APC and
Olig2 at a reduced level and fail to mature into oligodendrocytes
that are able to myelinate. Although it is highly probable that
Rheb1 loss in oligodendrocyte lineage cells is crucial for the
impaired oligodendrocyte differentiation and myelin formation
in the Rheb1 f/f,Nes-cre mice, it is likely that Rheb1 loss in
neurons also contributes to some extent. This notion is sup-
ported by the recent report using neuronal serum response
factor (SRF) knockout to show paracrine control of oligodendro-
cyte differentiation by SRF-directed neuronal gene expression
(Stritt et al., 2009). The present genetic models will afford lineage
and kinetic studies required to firmly establish how Rheb1
affects myelination in vivo.
Rosa26-Rheb1 S16H transgenicmice exhibit6-fold increase
of mTORC1, which appears comparable to that reported in TSCmental Cell 20, 97–108, January 18, 2011 ª2011 Elsevier Inc. 105
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phenotypes related to increased mTORC1 activity similar to
Pten knockout. All show increased brain size and enlargement
of neuronal soma (Kwon et al., 2003; Tavazoie et al., 2005;
Zeng et al., 2008), which is likely mediated by increased S6K1
(Pende et al., 2004). However, Rosa 26-Rheb1 S16H mice do
not show hypomyelination in either adolescent or adult animals
(Figures 6A–6D; Figures S6I–S6L). This is surprising because
TSC1 or TSC2 KO mice show hypomyelination that is thought
to be due to increased mTOR activity because it is partially
rescued by rapamycin (Meikle et al., 2008). In this study, rapamy-
cin was administered for >5 weeks, starting at early postnatal
stage (P5–P7) and did not inhibit myelination in control mice
(Meikle et al., 2008). However, another study reported that
rapamycin treatment of wild-type P21 mice for 3 weeks caused
hypomyelination (Narayanan et al., 2009). Our finding that
Rosa26-Rheb1 S16H transgenic mice do not exhibit hypomyeli-
nation suggests that mechanisms independent of Rheb1/
mTORC1 may contribute to the myelin deficit caused by TSC1
or TSC2 mutation.Concluding Remarks
We report the generation and characterization of Rheb1 and
Rheb2 knockout, and Rheb1 transgenic mice. We show that
Rheb1, but not Rheb2, is required for mTORC1 activation
in vivo, and neither Rheb1 nor 2 is essential for mTORC2 activa-
tion. Although Rheb1-mediated mTORC1 activity is critical
for the embryonic survival, it is not critical for the embryonic
brain formation because neurons, astrocytes, and OPCs
are formed in the absence of Rheb1. Instead, Rheb1 plays a
critical role in the regulation of their subsequent cell type-
specific adaptations, e.g., myelination during postnatal brain
development.EXPERIMENTAL PROCEDURES
Generation of Rheb1 and Rheb2 Knockout Mice
The exon 3 of Rheb1 is ‘‘floxed’’ and the first two coding exons of Rheb2 are
‘‘floxed’’ in the corresponding targeting vector. In both cases the mutant
protein lacks the N-terminal region that contains GTP-binding domain that is
critical for the normal functioning of Rheb. The Rheb1 and Rheb2 gene-target-
ing vectors illustrated in Figures S1A and S1D were constructed using stan-
dard molecular biology. The targeting vector was electroporated into embry-
onic stem (ES) cells, and the transfected ES clones were selected for G418
resistance according to standard protocols. The G418-resistant ES clones
with targeted homologous recombination were screened by PCR and further
confirmed by Southern blotting (Figure S1B). Confirmed ES clones were
injected into blastocyst mouse embryos to generate chimeric mice. The
chimeric mice were crossed with C57BL/6 mice to validate germline transmis-
sion. The offspring with ‘‘floxed’’ Rheb1 or 2 were crossed with Actin-cre or
Nes-Cre transgenic mice to generate germline or CNS-specific deletion of
Rheb1 or 2. The genotype of the ‘‘floxed’’ mice was determined by PCR on
tail genomic DNA using DNA primers as follows: Rheb1 50-GCC CAG AAC
ATC TGT TCC AT-30 and 50-GGT ACC CAC AAC CTG ACA CC-30 to amplify
wt and 50 floxed allele (wt, 650 bp; floxed allele, 850 bp); Rheb2 50-TTT TGG
TTT TCC TTG GC T TG-30and 50-GTG ATT CGA TGC ATT CAG TGA-30 (wt,
570 bp; floxed, 861bp). The Cre-mediated excision in Rheb1 and Rheb2
knockout mice was confirmed by PCR amplification of genomic DNA using
primers (50-ATA GCT GGA GCC ACC AAC AC-30, and 50-GCC TCA GCT
TCT CAA GCA AC-30 for Rheb1 to amplify a 750 bp product; and 50-TTT
GGT TTT CCT TGG CTT GC GGG-30 and 50-TGC ACA CTG CTA ACA GCT
CAA TGC-30 for Rheb2 to amplify a 540 bp product) and subsequently by106 Developmental Cell 20, 97–108, January 18, 2011 ª2011 Elsevieamplification and sequencing of mutant Rheb1 and Rheb2 transcripts. The
primers for the amplication of Cre are 50-TGC CAC GAC CAA GTG ACA
GCA ATG-30 and 50-ACC AGA GAC GGA AAT CCA TGG CTC-30 with the am-
plicon of 400 bp. All mouse work was done in accordancewith the Animal Care
and Use Committee guidelines of Johns Hopkins University School of Medi-
cine and Sichuan University West-China Hospital.Generation of Conditional Rosa26-mycRheb1S16H TransgenicMice
The targeting vector to knock a cassette that permits conditional expression of
mycRheb1 S16H cDNA into Rosa26 locus was illustrated by the diagram in
Figure S7H. It was made using components of the Rosa26 targeting system
provided by Philippe Soriano (Soriano, 1999). The original PGK-neo sequence
was replaced by PGK-EM7-neo expression cassette in plasmid PL452
(Liu et al., 2003) to allow kanamycin and neomycin selection in E. coli and
ES cells, respectively. A CMV b-actin enhancer-promoter (Okada et al.,
1999) was placed upstream of the ‘‘floxed’’ PGK-EM7-neo-tPA sequence to
drive Rheb1 cDNA transcription once the floxed tPA (transcriptional stop) is
removed by Cre recombinase. This CMV- b-actin enhancer-promoter has
been shown to be efficient in driving transgene expression when knocked
into Rosa26 locus (Zong et al., 2005). The targeting vector was electroporated
into ES cells, and ES clones with targeted homologous recombination was
identified by two sets of PCR primers coupled with sequencing of PCR prod-
ucts. Confirmed ES clones were injected into blastocyst mouse embryos to
generate chimeric mice. The chimeric mice were crossed with C57BL/6
mice to validate germline transmission. The genotype of the transgenic mice
was determined by PCRwith the following primers to distinguish wt or knockin
allele and Cre-mediated excision of the ‘‘stop’’ signal: WTF1 (forward), 50-GCA
CTT GCT CTC CCA AAG TC-3,0 and WTR1 (reverse), 50-GCG GGA GAA ATG
GAT ATG AA-30) to amplify wt allele (596 bp); FloxF (forward), 50-GCA ACG
TGC TGG TTA TTG TG-3,0 and FloxR (reverse), 50-GGG GAA CTT CCT GAC
TAG GG-30 to amplify the knockin allele (395 bp); and ExF (forward), 50-CAG
CCA TTG CCT TTT ATG GT-3,0 and ExR (reverse), 50-ACC ACC ACC ACC
ATT GAG AT-30 to amplify an excision band of 609 bp, confirming the Cre-
mediated excision of the ‘‘floxed’’ PGK-neo and ‘‘stop’’ signal.Insulin and Amino Acid Stimulation
Primary MEFs routinely cultured with DMEM culture medium with 10% FBS
were subjected to serum starvation (0.5% FBS) for 16 hr before insulin stimu-
lation (200 nM) for 15 min. Before amino acid stimulation, the serum-starved
MEFs were washed once with Dulbecco’s phosphate-buffered saline (dPBS;
GIBCO) and then incubated with dPBS for 2 hr before adding a mixture of
amino acids prepared with dPBS. The amino acid stimulation lasted for 1 hr
before cells were harvested for western blotting. The components of the amino
acid mixture are as follows: L-Arg, 84 mg/l; L-Cys, 48 mg/l; L-Glu, 584 mg/l;
L-His, 42 mg/l; L-Ile, 105 mg/l; L-Leu, 105 mg/l; L-Lys, 146 mg/l; L-Met,
30 mg/l; L-Phe, 66 mg/l; L-Thr, 95 mg/l; L-Trp, 16 mg/l; L-Tyr, 72 mg/l; and
L-Val, 94 mg/l.Transfection and Immunostaining
Primary MEFs were grown on glass coverslips with DMEM containing 10%
FBS and were transfected with myc-tagged Rheb1 expression plasmid using
calcium-phosphate-DNA coprecipitation method. Immunostaining was per-
formed by standard procedure, as described in the Supplemental Experi-
mental Procedures.Tissue Processing, Immunohistochemistry, and Electron
Microscopy
Standard immunohistochemical procedures were performed as detailed in the
Supplemental Experimental Procedures. For quantification of immunopositive
cells on tissue sections, three to six sections from each three mouse per geno-
type were quantified using Image-Pro Plus software. The statistical analysis of
the data-paired t test was performed using GraphPad Prism software. For
electron microscopy, mice were perfused with 2% glutaraldehyde/2% para-
formaldehyde in 0.1 M cacodylate buffer. Corpus callosum and optic nerves
were dissected and postfixed overnight in the same fixative buffer. Tissues
were then processed as standard procedure before photographing.r Inc.
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Supplemental Information includes Supplemental Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.devcel.
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